Vomiting

Harmonia Healthcare Opens First Treatment Center in New Jersey with Chief Scientific Officer and TIME 100 Health Award Winner, Dr. Marlena Fejzo

Retrieved on: 
Giovedì, Maggio 2, 2024
Frustration, GDF15, Pregnancy, Woman, Nausea, Research, NVP, Entrepreneurship, Disease, TIME, Vomiting, HG, Patient, Hyperemesis gravidarum, Hospital, Quality of life, Nursing

NEW YORK, May 2, 2024 /PRNewswire/ -- Harmonia Healthcare, the specialty women's health platform focusing on underdiagnosed, undertreated, and otherwise dismissed female-specific diseases including severe nausea and vomiting in pregnancy (NVP) and hyperemesis gravidarum (HG), opened its first center in Red Bank, New Jersey today. A second location is planned for New York City this fall. The opening of the highly anticipated center—which will treat and innovate around HG—is led by an exemplary founding team including Co-Founder and President Leslie Gautam and Chief Scientific Officer Dr. Marlena Fejzo, who today received the TIME 100 Health Award in recognition of her groundbreaking research on the disease.

Key Points: 
  • Harmonia sets itself apart with its model of providing superior outpatient medical care and fostering seamless partnerships with patients, OB/GYNs, midwives, doulas, and other healthcare and pregnancy support professionals.
  • Harmonia's services offer a holistic approach to enhance the short- and long-term health outcomes and quality of life for both the mother and baby.
  • "Harmonia patients will benefit from the insights of our best-in-class leadership team including world-leading experts in hyperemesis gravidarum.
  • Visit www.harmoniahealthcare.com and follow us on Instagram at @harmoniahealthcare for updates on the opening of the New York location this fall.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Retrieved on: 
Martedì, Aprile 30, 2024
Pain, FDA, Omeprazole, Fungal infection, Gastroenterology, Lactulose, PIN, Skin, Clarithromycin, Nausea, Hyponatremia, Infection, Paracetamol, Amoxicillin, Cardiomyopathy, Duchenne muscular dystrophy, Helicobacter pylori, Vomiting, Patient, Idiopathic pulmonary fibrosis, Constipation, Granisetron, Multimedia, Health, Acetylcysteine, Fever, Ibuprofen

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.

Key Points: 
  • NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
  • A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care.

GNC Becomes First Major Retailer to Launch GLP-1 Support Program

Retrieved on: 
Lunedì, Aprile 29, 2024
Education, Creatine, Risk, GNC, HMB, Health, Nausea, Weight loss, Appetite, Facial muscles, SVP, Vomiting, Support, Diarrhea, Constipation, GI, Bone density, Prevalence

PITTSBURGH, April 29, 2024 /PRNewswire/ -- GNC, the global leader in health and wellness, today announced its unprecedented initiative to support individuals using GLP-1 agonists. GNC has officially become the world's first major retailer to establish an entire section dedicated to assisting GLP-1 users in managing the common side effects and challenges associated with treatment. The new support section will be featured in all 2,300-plus GNC locations across the United States.

Key Points: 
  • GNC has officially become the world's first major retailer to establish an entire section dedicated to assisting GLP-1 users in managing the common side effects and challenges associated with treatment.
  • The new support section will be featured in all 2,300-plus GNC locations across the United States.
  • "No matter where you are in life, regardless of age, gender or goals, GNC has always been a trusted source for support.
  • When combined with GNC's support program, we can expect the successful outcomes of GLP-1 therapy to grow as quickly as the program will."

Boehringer Ingelheim and Atlanta Braves Foundation Partner to Support Shelter Dogs in Need

Retrieved on: 
Venerdì, Aprile 26, 2024
Dog, Atlanta Braves, Moxidectin, Shelter, Boehringer Ingelheim, Pet, Ozzie Albies, Animal, Breeding, Love, Partnership, DSM-IV codes, Seizure, Dog days, Human, Philadelphia Phillies, Tablet, Family, Vomiting, Truist Park, Diarrhea, Lethargy, Atlanta, Season, Associate

DULUTH, Ga., April 26, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia and its NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) product, and the Atlanta Braves Foundation, the non-profit arm of the Atlanta Braves, are proud to announce a collaborative effort to support shelter adoptions across Braves Country.

Key Points: 
  • DULUTH, Ga., April 26, 2024 /PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia and its NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) product, and the Atlanta Braves Foundation, the non-profit arm of the Atlanta Braves, are proud to announce a collaborative effort to support shelter adoptions across Braves Country.
  • On August 21, there will be a special on-field check presentation to the Ozzie Albies Foundation during the Braves home game against the Philadelphia Phillies to support shelter animals.
  • "We are incredibly excited to be part of this pet-centric initiative," said Daniel Watkins, Head of U.S. Pet at Boehringer Ingelheim.
  • In addition to providing much-needed resources, Boehringer Ingelheim is also working to raise awareness about the importance of adopting shelter animals.

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Retrieved on: 
Martedì, Aprile 23, 2024
Neuro-Oncology (journal), First grade, FDA, Society, University, BRAF V600, Day One, Hospital, Acne, Safety, Food, Biopharmaceutical, Conference call, Nausea, Insurance, Conference, Research, Webcast, Viral, Speech, Fatigue, Human, Disease, BRAF, Vomiting, Patient, Medicine, Headache, Event, Rash, Constipation, Diagnosis, Head, Neoplasm, Upper respiratory tract infection, PRS, Xeroderma, Fever, Caregiver, Ageing, Pharmaceutical industry

BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.

Key Points: 
  • With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.
  • “We are very proud that our first approved medicine addresses this serious and life-threatening disease of childhood and adolescence.
  • BRAF is the most commonly altered gene in pLGG, with up to 75 percent of children having a BRAF alteration.
  • “This is a tremendous moment not only for Day One, but also for the broader pediatric brain tumor community.

Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida

Retrieved on: 
Lunedì, Aprile 15, 2024
National Conference, MD, Conference, Plasma, PONV, Vomiting, Patient, Amisulpride, Society, Detail, Pharmaceutical industry

WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the sustained response of amisulpride for the rescue treatment of postoperative nausea and vomiting (“PONV”) will be presented at the upcoming American Society of PeriAnesthesia Nurses (ASPAN) 2024 National Conference, which is being held April 14-18, 2024, in Orlando, Florida.

Key Points: 
  • WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the sustained response of amisulpride for the rescue treatment of postoperative nausea and vomiting (“PONV”) will be presented at the upcoming American Society of PeriAnesthesia Nurses (ASPAN) 2024 National Conference, which is being held April 14-18, 2024, in Orlando, Florida.
  • The data being presented relate to a prespecified pharmacokinetic (“PK”) subset of patients from a Phase III, randomized, multicenter, double-blind, placebo-controlled, parallel-group study in adult surgical patients with moderate to high risk of PONV who failed antiemetic prophylaxis.
  • The purpose of the analysis was to evaluate the plasma concentrations of a single dose of IV amisulpride 10 mg for rescue treatment of PONV.
  • “Based on what we believe to be encouraging results and corresponding PK data, we expect more healthcare providers to recognize the potential of PONV rescue treatment with amisulpride to enhance confidence in post-surgery and discharge outcomes.”
    Details of the poster presentation are as follows:
    Abstract Title: Documented Sustained Response of Intravenous Amisulpride for Rescue Treatment of Postoperative Nausea and Vomiting: Results from a Phase III Trial

Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

Retrieved on: 
Martedì, Aprile 30, 2024
Mental Health, Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Clinical Global Impression, Clozapine, NCE, XETRA, Safety, Psychiatry, MD, PANSS, Common, Extrapyramidal system, CNS, Schizophrenia, Vomiting, Incidence, Patient, Peripheral nervous system, Evenamide, Headache, Positive, Medication, Pharmaceutical industry

Study 008A was a four-week, international, randomized, double-blind and placebo-controlled add-on Phase II/III study performed in 45 centers in 11 countries in Europe, Asia and Latin America.

Key Points: 
  • Study 008A was a four-week, international, randomized, double-blind and placebo-controlled add-on Phase II/III study performed in 45 centers in 11 countries in Europe, Asia and Latin America.
  • 291 patients were randomized to treatment either with evenamide or placebo as add-on to their current antipsychotic therapy.
  • Two hundred and eighty of the 291 patients completed the study with only three patients discontinuing the study due to adverse events, two of them on evenamide and one patient on placebo who died during the study.
  • Ravi Anand, MD, Chief Medical Officer of Newron, stated: “The results seen in study 008A with evenamide are ground-breaking and unique from many perspectives.

Supergut, the Leader in GLP-1 Functional Foods, Accelerates Its Unprecedented Retail Expansion With Newest Partner, GNC

Retrieved on: 
Lunedì, Aprile 29, 2024
General Health, Food, Beverage, Health, Retail, Fitness & Nutrition, Brain, Malnutrition, Digestion, Walmart, GNC, Bristol Farms, Nausea, Overweight, Diabetes, Insurance, Weight loss, Partnership, GLP-1, Atrophy, Prescription, Obesity, Food industry, Exercise, Science, Vomiting, Starch, Diarrhea, Metabolism, Constipation, Multimedia, Cardiovascular disease, Prediabetes, Immunity, Sleep, Injection, Dietary supplement

The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.

Key Points: 
  • The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.
  • In addition to this retail explosion, Supergut remains available on Supergut.com and Amazon .
  • “We’re excited to partner with GNC, which shares our values of scientific validation and customer education.
  • Approximately five million Americans take these drugs now, and up to 70 million Americans may use a GLP-1 by 2028 .

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

Retrieved on: 
Giovedì, Aprile 11, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Fear, Hospital, Safety, Nausea, Teva, TEVA, Doctor of Philosophy, Depression, Migraine, Light, Family, Vomiting, Patient, Aes, Molina Healthcare, Medication, Quality of life, Anxiety, Teva Pharmaceuticals, Sound

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.

Key Points: 
  • Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients.
  • In the study, AJOVY achieved primary endpoint and all secondary endpoints, significantly reducing the number of migraine days experienced per month, demonstrating superior efficacy over placebo.
  • Study data also show AJOVY was safe and well tolerated with no emerging safety signals.
  • Additional findings from this study are planned for presentation at a medical meeting later this year.

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
Venerdì, Aprile 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.